RT001 was not prioritized over RT002; rather RT001 completed a phase-3 trial sooner because the development plan for RT001 was less robust. Specifically, RT001 went to phase-3 in crow’s feet without any head-to-head data vs Botox (or another botulinum toxin), while RT002 was tested vs Botox in the phase-2 BELMONT study, allowing proper dose selection for phase-3 as well as a duration-of-action comparison to Botox.
Thus, I would argue that, rather than expediting RT001, RVNC put RT002 on a more deliberate and rigorous development path, recognizing that RT002 was the more consequential asset.
Good question—thanks for asking.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.